



Agenda subject to change prior to July 11 meeting.

**Prescription Drug Affordability Board Meeting Agenda**  
**Friday, July 11, 2025 from 10:00 am - 1:00 pm**

Zoom Meeting Information:

[https://us06web.zoom.us/meeting/register/tZcvfu2tqD4pGdLLE78FEqllouhgDE0tavoh#/registration](https://us06web.zoom.us/join/https://us06web.zoom.us/meeting/register/tZcvfu2tqD4pGdLLE78FEqllouhgDE0tavoh#/registration)

- |   |                           |
|---|---------------------------|
| <b>Call to Order, Roll Call, &amp; Minutes Approval</b>   | <b>10:00 - 10:05 am</b>   |
| <b>Board Member &amp; Director Updates</b>  | <b>10:05 - 10:10 am</b>   |
| <b>Board Business</b>   | <b>10:10 - 10:40 am</b>   |
| <ul style="list-style-type: none"><li><i>The Board may meet in Executive Session to receive legal advice regarding use of data by the Board in setting an upper payment limit, pending litigation, section 24-4-105, C.R.S., and section 24-4-103(4)(a), C.R.S., pursuant to section 24-6-402(3)(a)(II), C.R.S.</i></li></ul>   |                           |
| <b>Public Comment</b>   | <b>10:40 - 11:00 am</b>   |
| <i>Comments will be limited to 2 minutes per person or organization.</i>  |                           |
| <b>Board Business<sup>1</sup></b>   | <b>11:00 - 11:45 am</b>   |
| <ul style="list-style-type: none"><li><i>Presentation on Stelara Biosimilars from PORTAL</i></li><li><i>APCD Data Validation - Cosentyx Validated Data Addendum</i></li><li><i>APCD Data Validation - Stelara Validated Data Addendum</i></li></ul>   |                           |
| <b>Break</b>  | <b>11:45 - 11:55 am</b>   |
| <b>Rulemaking Hearing</b>   | <b>11:55 am - 1:00 pm</b> |
| <i>Prescription Drug Affordability Board Rule 3 CCR 702-9: Part 4.3: Upper Payment Limit for Enbrel</i>   |                           |
| <ul style="list-style-type: none"><li><i>Rule Introduction</i></li><li><i>Witness Testimony</i><ul style="list-style-type: none"><li><i>Witness testimony will be limited to three minutes per person. The Board may ask questions to the person testifying regarding their testimony. The time limit will not count towards answering any of the Board's questions. We will try to get to every testimony during the rulemaking hearing. However, if you are not selected to speak due to time constraints, please submit written testimony and sign up to testify at the next rulemaking hearing.</i></li></ul></li><li><i>Board Deliberation</i></li></ul> |                           |

---

<sup>1</sup> It is important to note that the Board did not get to these agenda items during July 11 due to the rulemaking hearing being continued as needed. The Board may address these items at its next meeting on August 22, 2025.



**Agenda subject to change prior to July 11 meeting.**

*The Board may meet in Executive Session to discuss confidential, trade-secret, or proprietary information pursuant to sections 24-6-402(3)(a)(III), C.R.S., and 10-16-1404(3), C.R.S.*

*The Board may meet in Executive Session to receive legal advice pursuant to section 24-6-402(3)(a)(II), C.R.S.*

*If you are in need of an accommodation to access PDAB meetings or materials, please notify staff at [dora\\_ins\\_pdab@state.co.us](mailto:dora_ins_pdab@state.co.us).*

*Councilmembers of the Prescription Drug Affordability Advisory Council may attend the July 11, 2025, Prescription Drug Affordability Board Meeting and may participate in the meeting, which may include providing public comment.*